GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Operating Income

CRDF (Cardiff Oncology) Operating Income : $-48.65 Mil (TTM As of Dec. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Operating Income?

Cardiff Oncology's Operating Income for the three months ended in Dec. 2024 was $-12.57 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 was $-48.65 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Cardiff Oncology's Operating Income for the three months ended in Dec. 2024 was $-12.57 Mil. Cardiff Oncology's Revenue for the three months ended in Dec. 2024 was $0.15 Mil. Therefore, Cardiff Oncology's Operating Margin % for the quarter that ended in Dec. 2024 was -8,325.83%.

Warning Sign:

Cardiff Oncology Inc operating margin has been in a 5-year decline. The average rate of decline per year is -6.5%.

Cardiff Oncology's 5-Year average Growth Rate for Operating Margin % was -6.50% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cardiff Oncology's annualized ROC % for the quarter that ended in Dec. 2024 was -848.31%. Cardiff Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -2,304.67%.


Cardiff Oncology Operating Income Historical Data

The historical data trend for Cardiff Oncology's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Operating Income Chart

Cardiff Oncology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.09 -28.86 -39.90 -45.41 -48.65

Cardiff Oncology Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.33 -10.93 -12.55 -12.60 -12.57

Cardiff Oncology Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiff Oncology  (NAS:CRDF) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cardiff Oncology's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=-50.288 * ( 1 - 0% )/( (6.264 + 5.592)/ 2 )
=-50.288/5.928
=-848.31 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Cardiff Oncology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-50.288/( ( (2.297 + max(-10.153, 0)) + (2.067 + max(-9.41, 0)) )/ 2 )
=-50.288/( ( 2.297 + 2.067 )/ 2 )
=-50.288/2.182
=-2,304.67 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.618 + 0 + 1.047) - (9.825 + 0 + 1.993)
=-10.153

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.773 + 0 + 2.535) - (9.972 + 0 + 2.746)
=-9.41

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Cardiff Oncology's Operating Margin % for the quarter that ended in Dec. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-12.572/0.151
=-8,325.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Cardiff Oncology Operating Income Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiff Oncology Business Description

Traded in Other Exchanges
Address
11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
Executives
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum director 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Gary W Pace director C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar officer: Chief Medical Officer C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander officer: Chief Scientific Officer C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White director 310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage director C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Tod Smeal officer: Chief Scientific Officer 11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner officer: Chief Medical Officer 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru director C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin director C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob director
Vicki Kelemen officer: Exec. VP and COO 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116